This is a humanized IgG1 antibody using the same sequences as the therapeutic antibody tiragolumab. It selectively binds to TIGIT, which suppresses the immune response to cancer. TIGIT initiates an inhibitory signaling cascade via the cytoplasmic tail. When ligand binds, the tail is phosphorylated, ultimately inhibiting the phosphoinositide 3 kinase (PI3K)/mitogen-activated protein kinase (MAPK) signaling cascades. Tiragolumab is thought to work as an immune amplifier with other cancer immunotherapies such as Tecentriq (atezolizumab). The TIGIT pathway is distinct, but complementary to the PDL1/PD1 pathway. Dual blockade with tiragolumab and Tecentriq may help overcome immune suppression and restore the immune response.